KEYNOTE-042: Should Pembrolizumab Replace Chemo for a Broader Population of Patients with Advanced NSCLC? (BMIC-038)
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice. (11:04)